Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Maxim Group Reiterates $5 Price Target on Mast Therapeutics (MSTX)

Mast Therapeutics (MSTX) Offers Business Update; Phase 3 EPIC Enrollment Surpasses 90% Mark

January 7, 2016 8:06 AM EST

Mast Therapeutics, Inc. (NYSE: MSTX) provided a business update.

The Company reported that patient enrollment in the pivotal Phase 3 "EPIC" study of its lead product candidate, vepoloxamer (MST-188), in sickle cell disease recently surpassed the 90% mark. The Company expects to complete patient enrollment in February. Consistent with prior guidance, the Company expects to report top-line results in the second quarter of... More